Les nouvelles molécules anti-VIH : la place du raltégravir

Translated title of the contribution: New anti-HIV drugs: The place of raltegravir

C. Katlama*, R. Tubiana, R. Murphy

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Principles: Integrase is an essential HIV-1-specific enzyme that is an active target for antiretroviral drug development. Integrase has at least two functions: firstly, it catalyses the 3′ processing at both ends of the retrotranscribed DNA, stabilizing the protein and allowing it to transpose to the nucleus and, secondly, it inhibits strand transfer integration into the human DNA. Without integration, there can be no viral replication in the host cell. Studies: Recently, a new class of drugs that specifically inhibits strand transfer has been developed. Two of these drugs are in late stage development: raltegravir, which has just been approved for use in treatment-experienced patients, and elvitegravir, currently in phase III trials. Raltegravir is dosed twice daily and has few drug-drug interactions since it is a drug metabolized through the UGTA1 pathway and not through the cytochrome P450 complex. Clinical studies: In both treatment-naive and experienced patients, trials have demonstrated raltegravir to be highly effective. One of the very specific features of its activity is a rapid antiviral efficacy within few weeks compared to standard therapies. Conclusion: Raltegravir has an excellent tolerability and can be combined easily to other new drugs.

Translated title of the contributionNew anti-HIV drugs: The place of raltegravir
Original languageFrench
Pages (from-to)11-17
Number of pages7
Issue number1
StatePublished - Feb 2009


  • Antiretroviral drugs
  • Inhibitors of integrase
  • Raltegravir

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'New anti-HIV drugs: The place of raltegravir'. Together they form a unique fingerprint.

Cite this